Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Anne-Marie Asemissen"'
Autor:
Anne-Marie Asemissen, Feline von Feldmann, Roswitha Dickerhoff, Corinna Güsmer, Carsten Bokemeyer, Thorben Mährle
Publikováno v:
HemaSphere, Vol 7, p e8092624 (2023)
Externí odkaz:
https://doaj.org/article/86a05025157b4e0484ccac2073e9b8ac
Autor:
Leon-Gordian Koepke, Annika Heuer, Martin Stangenberg, Marc Dreimann, Lutz Welker, Carsten Bokemeyer, André Strahl, Anne Marie Asemissen, Lennart Viezens
Publikováno v:
Diagnostics, Vol 12, Iss 2, p 310 (2022)
Patients with new-onset malignant spinal lesions often have an urgent need for local spine intervention and systemic therapy. For optimal management, it is crucial to diagnose the underlying disease as quickly and reliably as possible. The aim of our
Externí odkaz:
https://doaj.org/article/a7c36625e3824c05a239b4abcff29af8
Autor:
Lisa B. Leypoldt, Markus Munder, Anne Marie Asemissen, Hartmut Goldschmidt, Carsten Bokemeyer, Raphael Lutz, Ullrich Graeven, Axel Benner, Britta Besemer, Rudolf Peceny, Manola Zago, Martin Görner, Mathias Hänel, Hans Salwender, Christoph Mann, Katja Weisel, Diana Tichy, Peter Staib, Yon-Dschun Ko, Anna Jauch, Hans Christian Reinhardt, Igor Wolfgang Blau
Publikováno v:
Leukemia, 36(3):885888
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5867a89ed42a6cc58c40fadafddd147
https://doi.org/10.1038/s41375-021-01431-x
https://doi.org/10.1038/s41375-021-01431-x
Autor:
Ilka Grewe, Thomas Theo Brehm, Benno Kreuels, Oliver M Steinmetz, Bernhard Dumoulin, Anne Marie Asemissen, Dennis Tappe, Michael Ramharter, Stefan Schmiedel
Publikováno v:
Journal of travel medicine. 29(7)
We report a Leishmania infantum reactivation in an immunocompetent patient manifesting as visceral leishmaniasis with secondary IgA nephropathy nine years after an initial episode of mucosal leishmaniasis, which had been treated with liposomal amphot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134be1fa02aa425a9e1586943a84b1d7
https://pubmed.ncbi.nlm.nih.gov/35285886
https://pubmed.ncbi.nlm.nih.gov/35285886
Autor:
Leon-Gordian Koepke, Annika Heuer, Martin Stangenberg, Marc Dreimann, Lutz Welker, Carsten Bokemeyer, André Strahl, Anne Marie Asemissen, Lennart Viezens
Publikováno v:
Diagnostics; Volume 12; Issue 2; Pages: 310
Patients with new-onset malignant spinal lesions often have an urgent need for local spine intervention and systemic therapy. For optimal management, it is crucial to diagnose the underlying disease as quickly and reliably as possible. The aim of our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a39135ac41709671908275c589e264c
https://pubmed.ncbi.nlm.nih.gov/35204401
https://pubmed.ncbi.nlm.nih.gov/35204401
Autor:
Philippe Schafhausen, Carsten Bokemeyer, Judith Dierlamm, Frank Dicker, Snjezana Janjetovic, Anne Marie Asemissen, Mascha Binder
Publikováno v:
Tumori Journal. 105:NP8-NP11
Background: Progression of chronic myeloid leukemia (CML) is frequently accompanied by cytogenetic evolution, with an extra copy of the Philadelphia chromosome, trisomy 8 and 19, and isochromosome (17p) commonly detected. Translocations involving 11q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::193eaba0dd1a9cad31fb58e254836146
https://doi.org/10.1177/0300891619839473
https://doi.org/10.1177/0300891619839473
Autor:
Lisa B. Leypoldt, Anne Marie Asemissen, Britta Besemer, Mathias Haenel, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Hans Christian Reinhardt, Peter Staib, Christoph Mann, Raphael Lutz, Markus Munder, Ullrich Graeven, Rudolf Peceny, Hans Salwender, Anna Jauch, Manola Zago, Axel Benner, Diana Tichy, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C. Weisel, German Speaking Myeloma Multicenter Group (GMMG)
Publikováno v:
SSRN Electronic Journal.
Background: High-risk (HR) multiple myeloma (MM) has an impaired prognostic outcome. Addition of anti-CD38 monoclonal antibodies to standard-of-care regimens improved response rates and depth of response. Here, we report a prespecified interim analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b70798192651ed5a20c75c16776d716
https://doi.org/10.2139/ssrn.3790459
https://doi.org/10.2139/ssrn.3790459
Autor:
Leon-Gordian Köpke, Lennart Viezens, Annika Heuer, André Strahl, Martin Stangenberg, Marc Dreimann, Anne Marie Asemissen
Publikováno v:
Brain and Spine. 2:100940
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::402124653592e8e5ac01fdfeb296b45b
https://doi.org/10.1016/j.bas.2022.100940
https://doi.org/10.1016/j.bas.2022.100940
Autor:
Markus Munder, Roland Fenk, Mathias Haenel, Steffen Luntz, Wolfgang Knauf, Martin C. Mueller, Anne-Marie Asemissen, Eva Nievergall, Ivana von Metzler, Tobias A. W. Holderried, Uta Bertsch, Elias K. Mai, Niels Weinhold, Deniz Gezer, Christoph Mann, Katja Weisel, Martin Hoffmann, Hans Salwender, Hartmut Goldschmidt, Britta Besemer, Karolin Trautmann-Grill, Stefanie Huhn, Cyrus Khandanpour, Jan Dürig, Joerg Thomalla, Diana Tichy, Katharina Kriegsmann, Marc-Steffen Raab, Thomas Geer, Bernhard Heilmeier, Roland Schroers, Hendrik Riesenberg, Maika Klaiber-Hakimi
Publikováno v:
Blood. 138:463-463
Background: In newly-diagnosed multiple myeloma (NDMM), lenalidomide/bortezomib/dexamethasone (RVd) is one of the most widely used combination regimens. Anti-CD38 monoclonal antibodies (CD38-moAb) increase efficacy when added to standard-of-care regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40acd634cbc8978c6878a405a39c237d
https://doi.org/10.1182/blood-2021-145097
https://doi.org/10.1182/blood-2021-145097
Autor:
Toni Thenhausen, Nuray Akyüz, Thorben Mährle, Sonja Loges, Eray Goekkurt, Julia Quidde, Alexander Stein, Carsten Bokemeyer, Benjamin Thiele, Anna Brandt, Simon Schliffke, Janina Radloff, Thomas Haalck, Mascha Binder, Anne Marie Asemissen, Christopher Thomas Ford, Artus Krohn-Grimberghe
Publikováno v:
International Journal of Cancer. 140:2535-2544
Cancer immunotherapy with antibodies targeting immune checkpoints, such as programmed cell death protein 1 (PD-1), shows encouraging results, but reliable biomarkers predicting response to this costly and potentially toxic treatment approach are stil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2e5c9b06dcbec51c32fea54d0d0addc
https://doi.org/10.1002/ijc.30549
https://doi.org/10.1002/ijc.30549